PA8801501A1 - ARILINDENOPIRIMIDINAS Y SU USO COMO ANTAGONISTAS DEL RECEPTOR A 2a DE ADENOSINA - Google Patents

ARILINDENOPIRIMIDINAS Y SU USO COMO ANTAGONISTAS DEL RECEPTOR A 2a DE ADENOSINA

Info

Publication number
PA8801501A1
PA8801501A1 PA20088801501A PA8801501A PA8801501A1 PA 8801501 A1 PA8801501 A1 PA 8801501A1 PA 20088801501 A PA20088801501 A PA 20088801501A PA 8801501 A PA8801501 A PA 8801501A PA 8801501 A1 PA8801501 A1 PA 8801501A1
Authority
PA
Panama
Prior art keywords
arylindenopirimidines
adenosine
receiver antagonists
antagonists
adenosine receiver
Prior art date
Application number
PA20088801501A
Other languages
English (en)
Spanish (es)
Inventor
C Shook Brian
F Jackson Paul
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of PA8801501A1 publication Critical patent/PA8801501A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PA20088801501A 2007-10-24 2008-10-23 ARILINDENOPIRIMIDINAS Y SU USO COMO ANTAGONISTAS DEL RECEPTOR A 2a DE ADENOSINA PA8801501A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US98224707P 2007-10-24 2007-10-24

Publications (1)

Publication Number Publication Date
PA8801501A1 true PA8801501A1 (es) 2009-05-15

Family

ID=40091927

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20088801501A PA8801501A1 (es) 2007-10-24 2008-10-23 ARILINDENOPIRIMIDINAS Y SU USO COMO ANTAGONISTAS DEL RECEPTOR A 2a DE ADENOSINA

Country Status (12)

Country Link
US (1) US8017614B2 (enExample)
EP (1) EP2217575A1 (enExample)
JP (1) JP2011500819A (enExample)
CN (1) CN101835759A (enExample)
AR (1) AR069009A1 (enExample)
AU (1) AU2008317034A1 (enExample)
CL (1) CL2008003131A1 (enExample)
PA (1) PA8801501A1 (enExample)
PE (1) PE20091344A1 (enExample)
TW (1) TW200934493A (enExample)
UY (1) UY31420A1 (enExample)
WO (1) WO2009055308A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110105540A1 (en) * 2009-10-29 2011-05-05 Jackson Paul F 2-AMINO-9-[4-(4-METHOXY-PHENOXY)-PIPERIDIN-1-YL]-4-PHENYL-INDENO[1,2-D]PYRIMIDIN-5-ONE AND ITS USE AS A HIGHLY SELECTIVE ADENOSINE A2a RECEPTOR ANTAGONIST
JP5916730B2 (ja) * 2010-09-06 2016-05-11 グアンジョウ インスティテュート オブ バイオメディスン アンド ヘルス,チャイニーズ アカデミー オブ サイエンスィズ アミド化合物
ES2627541T3 (es) 2012-04-20 2017-07-28 Ucb Pharma, S.A. Métodos para tratar la enfermedad de Parkinson
CN113727999A (zh) 2019-01-11 2021-11-30 奥默罗斯公司 用于治疗癌症的方法和组合物
KR20250004779A (ko) 2022-04-13 2025-01-08 길리애드 사이언시즈, 인코포레이티드 Trop-2 발현 암을 치료하기 위한 병용 요법
WO2025137640A1 (en) 2023-12-22 2025-06-26 Gilead Sciences, Inc. Azaspiro wrn inhibitors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040127510A1 (en) * 2002-04-16 2004-07-01 Heintzelman Geoffrey R. Arylindenopyridines and arylindenopyrimidines and related therapeutic and prophylactic methods
AU2003275430A1 (en) 2003-10-03 2005-05-19 Ortho-Mcneil Pharmaceutical, Inc. Arylindenopyridines and arylindenopyridines and their use as adenosine a2a receptor antagonist

Also Published As

Publication number Publication date
WO2009055308A1 (en) 2009-04-30
AR069009A1 (es) 2009-12-23
JP2011500819A (ja) 2011-01-06
US8017614B2 (en) 2011-09-13
UY31420A1 (es) 2009-04-30
EP2217575A1 (en) 2010-08-18
TW200934493A (en) 2009-08-16
AU2008317034A1 (en) 2009-04-30
CL2008003131A1 (es) 2010-02-19
PE20091344A1 (es) 2009-09-24
CN101835759A (zh) 2010-09-15
US20090111827A1 (en) 2009-04-30

Similar Documents

Publication Publication Date Title
UY28766A1 (es) Compuestos heteropolicíclicos adicionales y su uso como antagonistas del receptor de glutamato metabotrópico
SV2010003662A (es) Derivados de azetidina y ciclobutano como inhibidores de jak ref. x-19081
CO6361994A2 (es) Antagonistas del receptor de orexina de isonicotinamida
ECSP088279A (es) Ciclopropil aminas como moduladores del receptor de histamina h3
PA8772101A1 (es) Imidazol-triazolopirimidinas sustituidas
PA8548901A1 (es) Ligandos del receptor 5-ht y sus usos
CR10249A (es) Compuestos de amino- pirimidina 2,6-sistituidos -4-monosustituidos como antagonistas del receptor de prostaglandina d2
CL2008003159A1 (es) Compuestos derivados de diaminas sustituidas, sus sales farmaceuticamente aceptables o sus solvatos; compuestos intermediarios; utiles como agentes antiobesidad, mediados por la inhibicion del receptor npy y5.
GT201000179A (es) "antagonistas del receptor mineralcorticoide y metodos de uso"
UY29899A1 (es) Uso de flibanserina para el tratamiento de trastornos del deseo sexual premenopausicos
ECSP11010977A (es) Metilenaminas de tieno[2,3-d] pirimidina y su uso como antagonistas
CO6280470A2 (es) Bis-piridilpiridonas como antaginistas del receptor 1 de la hormona concentradora de la melanina
BRPI0614397A2 (pt) compostos de pirimidina como moduladores de receptor de serotonina
UY31420A1 (es) Arilindenopirimidinas y su uso como antagonistas del receptor a2a de adenosina
SV2005002061A (es) Derivados de piridilo y su uso como antagonistas del receptor mglu5 ref. x-16538
CU23899B1 (es) Benzotiazoles como moduladores del receptor de grelina
PA8806501A1 (es) Triazolotriazinas y triazolopirazinas y su uso
UY31717A1 (es) (pirazolilcarbonil) imidazolidinonas sustituidas y su uso
PA8801401A1 (es) Arilindenopirimidinas y su uso como adenosina a2a
ECSP12011842A (es) ARILINDENOPIRIMIDINAS SUSTITUIDAS CON ALQUILO Y SU USO COMO ANTAGONISTAS DEL RECEPTOR DE ADENOSINA A2a ALTAMENTE SELECTIVOS
PA8567701A1 (es) Agonistas del receptor b3-adrenergico
CL2008001007A1 (es) Compuestos derivados de furo[2,3-b] piridina, moduladores del receptor canabinoide-1; y su uso para tratar psicosis, deficit de memoria, trastornos cognitivos, entre otras enfermedades.
CL2015000890A1 (es) Compuestos derivados de etinilo como moduladores de la actividad del receptor mglur5; proceso de obtencion; composicion farmaceutica que lo contiene; uso en el tratamiento de ansiedad, dolor, depresion, enfermedad de parkinson, entre otras.
ECSP12011840A (es) Arilindenopirimidinas sustituidas con heteroarilo y su uso como antagonistas del receptor de adenosina a2a altamente selectivos
ECSP12011844A (es) 2-amino-9-[4-(4-metoxi-fenoxi)-piperidin-1-il]-4-fenil-indeno[1,2-d]pirimidin-5-ona y su uso como un antagonista del receptor de adenosina a2a altamente selectivo